In-vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp.
Open Access
- 1 August 1999
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 44 (2) , 283-286
- https://doi.org/10.1093/jac/44.2.283
Abstract
UR-9825 is a new broad-spectrum triazole antifungal agent with a good pharmacokinetic profile and excellent bioavailability. It shows high in-vitro activity and efficacy in models of systemic candidosis in rats and rabbits, comparing favourably with fluconazole. The purpose of this study was to evaluate the in-vitro activity of UR-9825 and to compare it with that of fluconazole and itraconazole against 283 clinical isolates of Candida spp. UR-9825 was more potent against Candida spp. than both fluconazole and itraconazole, even against some Candida albicans and Candida krusei isolates with decreased susceptibility to fluconazole (MIC 16 mg/L).Keywords
This publication has 7 references indexed in Scilit:
- New Azole Antifungals. 3. Synthesis and Antifungal Activity of 3-Substituted-4(3H)-quinazolinonesJournal of Medicinal Chemistry, 1998
- In vitro evaluation of voriconazole against some clinically important fungiAntimicrobial Agents and Chemotherapy, 1997
- International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal InfectionsClinical Infectious Diseases, 1997
- In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida speciesAntimicrobial Agents and Chemotherapy, 1996
- Correlation of in-vitro susceptibility test results with clinical response: a study of azole therapy in AIDS patientsJournal of Antimicrobial Chemotherapy, 1995
- Improved medium for fluconazole susceptibility testing of Candida albicansAntimicrobial Agents and Chemotherapy, 1994